NASDAQ: CARLCarlsmed Inc Stock
$11.33-0.33 (-2.83%)
Updated Jul 20, 2026
CARL Price
$11.33
Fair Value Price
N/A
Market Cap
$308.01M
52 Week Low
$8.50
52 Week High
$17.19
P/E
-5.25x
P/B
3.34x
P/S
4.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$56.44M
Earnings
-$32.60M
Gross Margin
75.9%
Operating Margin
-55.31%
Profit Margin
-57.8%
Debt to Equity
0.29
Operating Cash Flow
-$34M
Beta
1.21
Next Earnings
Aug 27, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CARL Overview
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CARL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
C
CARL
Ranked#35 of 41
Ranked#35 of 41
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $45.22 | A | |
| $6.51 | A | |
| $70.50 | B |
Be the first to know about important CARL news, forecast changes, insider trades & much more!
CARL News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CARL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CARL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CARL is good value based on its book value relative to its share price (3.34x), compared to the US Health Information Services industry average (3.39x)
P/B vs Industry Valuation
CARL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CARL due diligence checks available for Premium users.
Valuation
CARL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.25x
Industry
12.42x
Market
11.71x
CARL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.34x
Industry
3.39x
CARL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CARL's financial health
Profit margin
Revenue
$16.1M
Net Income
-$8.7M
Profit Margin
-54%
CARL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CARL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$118.8M
Liabilities
$26.5M
Debt to equity
0.29
CARL's short-term assets ($115.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CARL's short-term assets ($115.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CARL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.0M
Investing
-$206.0k
Financing
$436.0k
CARL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CARL vs Health Information Service Stocks
Carlsmed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.